Monday, December 06, 2021 4:03:52 PM
Unfortunately it is incorrect. I'm guessing they are confused about the "Fully Diluted Outstanding" which is when you add in all the Common conversions that are possible so you know that there is enough Authorized to cover it all even if they all converted at once.
Preferred can't be counted both as Preferred and as "reserved" Common at the same time. That makes no sense whatsoever.
Unless one was making things up trying to trivialize or explain away the mystery shares that are in the Outstanding.
Preferred can't be counted both as Preferred and as "reserved" Common at the same time. That makes no sense whatsoever.
Unless one was making things up trying to trivialize or explain away the mystery shares that are in the Outstanding.
Recent BRTX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/13/2026 09:22:23 PM
- BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical Platform • GlobeNewswire Inc. • 04/07/2026 12:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/03/2026 06:46:20 PM
- BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/30/2026 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/26/2026 08:20:29 PM
- BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 03/19/2026 12:00:00 PM
- BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026 • GlobeNewswire Inc. • 03/05/2026 01:00:00 PM
- BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy • GlobeNewswire Inc. • 03/04/2026 01:00:00 PM
- BioRestorative secures Australian patent protection for ThermoStem® obesity therapy platform • IH Market News • 02/24/2026 03:14:07 PM
- BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs • GlobeNewswire Inc. • 02/24/2026 01:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/23/2026 09:50:39 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/18/2026 09:12:24 PM
- BioRestorative Announces Closing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/14/2026 01:30:00 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/13/2026 02:48:15 PM
- BioRestorative Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 02/12/2026 03:30:00 AM
- BioRestorative Announces Positive Outcome from Type B Meeting with FDA • GlobeNewswire Inc. • 02/11/2026 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/10/2026 10:20:59 PM
- BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/09/2026 10:31:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/12/2025 10:11:16 PM
